InvestorsHub Logo
Followers 20
Posts 5354
Boards Moderated 0
Alias Born 01/04/2012

Re: silvr_surfr post# 14518

Tuesday, 10/17/2023 4:12:00 PM

Tuesday, October 17, 2023 4:12:00 PM

Post# of 14916
Silvr, according to Pfizer's Q2 presentation The Vyndaquel family of products accounted for 6.1% of their revenue and grew revenue by 43% over the previous year.

The LOE for the US is 2024, but they have a Patent Term Extension pending which should take it to 2028. Whereas the EU LOE expires in 2026.

A generic is already approved for FoldRX Pharms. So I imagine they will want to get it approved in the EU in 2025, which gives them time to switch existing patients to the new version.

Q2 Presentation
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ANIP News